The pharmaceutical firm, Sequent Scientific Ltd., is about 30 years old. It has an international footprint functioning in the line of animal health and specialty chemicals. Sequent Scientific is the biggest active pharmaceutical ingredients manufacturer in the nation, around the globe. Since it was the first one in the industry, Sequent Scientific practically holds a monopolistic business in the nation. Throughout Spain, India, Germany, Brazil, and Turkey, Sequent Scientific has 8 manufacturing plants.
The company’s presence is spread throughout over 100 nations with approvals granted by international regulatory agencies such as the WHO, TGA, and the USFDA. When it comes to veterinary APIs, Sequent Scientific’s Vizag facility is the first and the only USFDA approved facility in India. Its chief focus lies on livestock and poultry products. It also offers lab and technical support facilities.
Sequent is also of use to the female healthcare sector with the importance on steroids and hormones directing attention to numerous therapeutic classifications. It also works throughout API therapeutic sectors, for instance, anti-infective, anti-malarial, antibiotic, central nervous system, muscle relaxant, anti-hypertensive, dermatology, and anti-cancer. A couple of years ago, the firm bought a niche veterinary health firm based in Germany. With this purchase, it is hoped to consolidate the place Sequent holds in the European market. The firm dispatched calendar year 2019 on a very optimistic note and hopes to take ahead the advancement momentum with return ratios rising and paving the way to robust operational cash flows.
According to the latest reports, private equity investors are in primary discussions to buy Sequent Scientific Ltd., the animal healthcare firm. The purchase will probably be around Rs. 2,500 crores and will witness the departure of founder promoters of Sequent, namely, Arun Kumar, KR Ravishankar with family, which hold almost a 56.5% stake in the firm.